Why the study?
Does aspirin 325 mg improve vein graft survival and mortality in patients post coronary bypass surgery compared to lower doses?
Does aspirin 325 mg improve vein graft survival and mortality in patients post coronary bypass surgery compared to lower doses?
Aspirin 325 mg appears to be the optimal dose for improving vein graft survival and mortality post-CABG without increasing complications.
Favors 325 mg aspirin post-CABG to optimize graft survival and mortality; confirms superiority over lower doses in Level 1 evidence.
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was, what is the optimal dose of aspirin post cardiac surgery that should be given to prevent graft occlusion and prolong survival. Altogether, 114 papers were found from Medline and 59 papers were found from the Cochrane Central Register of Controlled Trials using the reported search, of which seven presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of these papers are tabulated. We conclude that best evidence suggests that 325 mg optimally improves vein graft survival and mortality, and does not cause an increase in complications compared to lower doses.
No takes yet. Share an insight, caveat, or question.
Joel Dunning (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: